Immunologic and Predictive Features of MIS-C

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 5R01HD108467-02

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2022
    2024
  • Known Financial Commitments (USD)

    $572,109
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    Dusan Bogunovic
  • Research Location

    United States of America
  • Lead Research Institution

    ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Children (1 year to 12 years)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The novel SARS coronavirus (SARS-CoV-2) causes the severe pneumonia-like coronavirus disease (COVID-19). SARS-CoV-2 infected over 170 million individuals and has claimed over 3.5 million lives worldwide to date. If otherwise healthy, children were thought to be largely spared from SARS-CoV-2 disease. However, in areas of high SARS-CoV-2 infection rates, some children started presenting to pediatric critical care units 4-6 weeks following SARS-CoV- 2 infection with Kawasaki-like disease. Clinically, we now know that this is a distinct disease, which was recently termed - multisystem inflammatory syndrome in children (MIS-C). While the characteristic clinical features of MIS-C are becoming clear, the pathophysiology remains unknown. Here we propose to evaluate three independent cohorts of MIS-C during acute and convalescent phases of disease at clinical, genetic and immunologic levels using the latest technology. We will not only perform systemic immunological mapping of MIS-C as compared to controls, but also utilize machine learning algorithms to delineate how best to predict, diagnose and outcome stratify MIS-C. We anticipate discovering immunologic and genetic features which can aid us in assessing risks of MIS-C development, diagnosis and prognosis. In summary, our systematic analysis and computational modeling of the clinical and immune features of MIS-C will not only help illuminate the pathogenesis of this syndrome, but will also provide us with actionable biomarkers for disease risk, diagnosis and progression.